258 results about "Ovary cancer" patented technology

An antigen peptide is provided specifically for treating individuals suffering from ovarian cancer, preferably based on BRCA1 gene c. 5470_5477del8 mutation. It is selected from amino acid sequences of SEQ ID NO. 1 to SEQ ID NO. 6, or derived by substitution, deletion and / or addition of at least one amino acid. The neoantigen polypeptides of the present disclosure can significantly activate T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro, stimulating the release of the cytokine IFN-y, indicating notable immunogenicity. This enhances T lymphocytes' ability to target and kill cancer cells from ovarian cancer patients carrying the BRCA1 gene c. 5470_5477del8 mutation. Additionally, the antigen peptide can activate and expand human T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro for adoptive cell therapy. The antigen peptide of the present disclosure addresses the gap in personalized antigen peptide therapies for ovarian cancer patients with BRCAl-c. 5470_5477del8 somatic mutations.

The invention relates to the field of antitumor drugs, in particular to a thiophene acetyl tetrahydro-beta-carboline compound and application thereof. The thiophene acetyl tetrahydro-beta-carboline compound or the pharmaceutically acceptable salt thereof, and the pharmaceutical composition containing the compound can be used for preparing medicines for preventing and / or treating various cancers. The cancer is at least one of breast cancer, lung cancer, osteosarcoma, melanoma, gastric cancer, pancreatic cancer, kidney cancer, glioma and ovarian cancer. Activity screening is carried out on various compounds, it is found for the first time that the 12 compounds provided by the invention have remarkable broad-spectrum inhibitory activity on various human cancer cell lines, and key candidate compounds are provided for developing novel anti-cancer drugs.

The invention discloses an ovarian cancer postoperative low blood volume shock risk dynamic prediction system, and relates to the field of clinical prediction models, and the system comprises a clinical parameter collection module which is used for obtaining a plurality of perioperative period clinical parameters related to postoperative low blood volume shock; the risk calculation engine performs weighted integration on the clinical parameters based on a multi-factor regression model to generate an individualized risk score; the visual output module is used for displaying the contribution degree of each parameter and the overall risk level; and the real-time risk trend prediction module is used for collecting physiological parameter dynamic change data at multiple time points after an operation, quantifying a risk change trend by calculating a risk evolution index, and fusing the index with a static risk value to generate a final risk score. According to the scheme, the early recognition capability and prediction precision of the postoperative low blood volume shock risk can be remarkably improved.

A multimodal deep learning framework which is used to determine the likelihood of a particular treatment method effectively treating a patient with ovarian / kidney cancer with the goal of increasing patient survival. The framework takes into account not only large histopathology images (whole slide images), but also clinical variables to increase the scope of the data. The results demonstrate that the proposed models achieve high prediction accuracy and interpretability and can also be transferred to other cancer datasets without significant loss of performance. One of the key innovations here is the combination of pathology and clinical variables in a deep learning model to provide recommendations in therapy areas with limited information.

The application discloses an 8-hydroxyquinoline anticancer zinc (II) complex and a synthesis method and application thereof. The 8-hydroxyquinoline anticancer zinc (II) complex is synthesized by taking 5,7-diiodo-8-hydroxyquinoline, 5,7-dichloro-8-hydroxyquinoline, 5-chloro-7-iodo-8-hydroxyquinoline, 5,7-dibromo-8-hydroxyquinoline and 5-chloro-8-hydroxyquinoline as a first ligand and taking 4,4'-dimethoxy-2,2'-bipyridine, 4,4-di-tert-butyl-2,2-bipyridine, 5,5'-dimethyl-2,2-bipyridine, 2,2-bipyridine and 4,4'-dimethyl-2,2'-bipyridine as auxiliary ligands. The 8-hydroxyquinoline anticancer zinc (II) complex has good inhibiting effect on SK-OV-3CR cells of an ovarian cancer drug-resistant strain, is higher than that of cisplatin drugs, overcomes drug resistance of clinical drugs, has potential medicinal value and can be used for preparation of various antitumor drugs.

The application discloses a pyrrolobenzodiazepine-anthracene imide hybrid molecule and a preparation method and application thereof, and belongs to the technical field of chemical medicines. In order to solve the problems of few kinds of warheads of an existing antibody drug conjugate, single action mechanism and drug resistance easily generated in long-term use, a pyrrolobenzodiazepine-anthracene imide hybrid molecule shown in formula I and a preparation method and application thereof are provided. Experimental results show that the compound has strong anti-proliferation activity in various tumor cells such as ovarian cancer cells, gastric cancer cells and breast cancer cells, and an antibody drug conjugate thereof has good in-vivo and in-vitro anti-tumor activity and good safety.

Provided is use of a KIF18A inhibitor in preparing a medicament for treating ovarian cancer disease. Pharmacological studies have demonstrated that compounds 1-3 can inhibit the growth of ovarian cancer heterogeneous tumors, and a high dose of the compounds can cause tumor regression in mice. Compared with AMG650, a lower drug exposure of compounds 1-3 reduces the potential drug accumulation toxicity and possesses a significant therapeutic effect on ovarian cancer with good safety.

This invention relates to the field of biomedical technology, providing the application of glycoprotein tumor biomarkers in the preparation of cancer diagnostic reagents. The glycoprotein tumor biomarker is a CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification. This invention utilizes CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification as a pan-cancer biomarker, combining it with existing conventional tumor markers (CEA, CA19-9, CA50, CA242, CA72-4, CA125, CA15-3, AFP, SCC, CYFRA21-1, PROGRP, NSE, HE-4, or PSA) for early cancer screening, assessment, diagnosis, postoperative monitoring, and / or prognostic analysis, particularly for the diagnosis of pancreatic cancer, cholangiocarcinoma, gastric cancer, lung cancer, breast cancer, or ovarian cancer.

Provided herein are, inter alia, novel antibodies that bind to V-domain Ig suppressor of T-cell activation (VISTA) thereby effectively targeting cells expressing VISTA. The antibodies provided herein may be used, inter alia, for therapeutic cancer applications, including, in some embodiments, treatment of multiple cancer types, which may include lung cancer, breast cancer, pancreatic cancer, ovarian cancer, colorectal cancer, renal cancer, or glioblastoma.

A kind of H&E image ovarian cancer polyploid giant cell (PGCCs) detection method based on deep learning, including constructing specific data set, image annotation and data division, using OCDet model to carry out feature learning and optimization, and model training and evaluation.The method first establishes the H&E staining image data set containing PGCCs, then accurately labels the image and divides it into training, verification and test set.OCDet model takes CSPDarkNet as the core, combines ECA mechanism, focuses on the deep learning and re-encoding of pathological semantic features.Through the training data set, the model updates parameters through back propagation and gradient descent, optimizes to identify PGCCs features.The verification set is used for model tuning, and the test set is used for evaluating the performance of the model.The automatic detection technology of the application can help doctors improve the diagnosis efficiency and reduce the error, provide an important reference for clinical treatment and prognosis evaluation, and show significant clinical application value.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

The invention discloses application of a small molecule compound in preparation of a medicine for treating ovarian cancer, and belongs to the technical field of biological medicine. The small molecule compound comprises a structure as shown in a formula (I) or an isomer, a pharmaceutically acceptable solvate or salt thereof, it is found for the first time that the small molecule compound can effectively reduce protein expression of YBX1, and meanwhile in-vitro verification experiments prove that the small molecule compound has a remarkable inhibition effect on proliferation of ovarian cancer cells. In addition, it is found that the small molecule compound can improve the cytotoxicity of cis-platinum and significantly enhance the anti-tumor effect of cis-platinum. The application of the small molecule compound YB-B1 targeting YBX1 in preparation of the medicine for treating the ovarian cancer is disclosed for the first time, a new method and a new idea are provided for clinical treatment of the ovarian cancer, and the small molecule compound YB-B1 particularly has remarkable significance in auxiliary treatment and prevention and treatment of cis-platinum drug-resistant ovarian cancer.

The invention relates to application of a PARP inhibitor in cancer treatment, in particular to application of the PARP inhibitor in ovarian cancer maintenance treatment. More specifically, the present invention provides a maintenance therapy for an ovarian cancer patient comprising administering an effective amount of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl) piperazine-1-carbonyl) benzyl) quinazoline-2, 4 (1H, 3H)-dione, a hydrate or a pharmaceutically acceptable salt thereof, to an ovarian cancer patient who has undergone a first-line platinum-containing regimen treatment and achieves complete or partial remission, or a pharmaceutical composition containing 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl) piperazine-1-carbonyl) benzyl) quinazoline-2, 4 (1H, 3H)-dione, a hydrate thereof, or a pharmaceutically acceptable salt thereof, or a medicament containing the pharmaceutical composition.

A felodipine liposome, and the preparation and use thereof. The felodipine liposome comprises felodipine, a phospholipid and cholesterol, wherein the mass ratio of the felodipine to the phospholipid is 1:8 to 1:20; and the mass ratio of the phospholipid to the cholesterol is 5:1 to 20:1. Furthermore, the felodipine liposome may further contain octadecylamine, wherein the mass ratio of the cholesterol to the octadecylamine is 1:1 to 1:3. The use of the felodipine or felodipine liposome or felodipine liposome lyophilized powder in the preparation of an anti-tumor drug. The tumor is colorectal cancer, liver cancer, ovarian cancer or breast cancer, and in particular, the felodipine or felodipine liposome or felodipine liposome lyophilized powder exhibits the most potent inhibitory effect on colorectal cancer.

The invention discloses an MEK / HDAC double-target inhibitor as well as a synthesis method and application thereof, and belongs to the technical field of medicines. Through molecular docking and in-vitro thermodynamic migration experiments, the applicant finds that the inhibitor not only can stabilize MEK and HDAC proteins, but also can be specifically combined with the MEK and HDAC proteins in an intracellular environment; protein immunoblotting experiments find that the inhibitor can inhibit reactivation of ERK, overcomes the limitation of a single-target inhibitor in curative effect and activity, and significantly improves the drug resistance problem of trametinib in ovarian cancer treatment and various EGFR-TKI treatment in non-small cell lung cancer treatment; furthermore, an in-vitro anti-tumor activity experiment shows that the IC50 value of the MEK / HDAC inhibitor on tumor cells from human ovarian cancer and various lung cancers is 0.07-10 mu M, and the MEK / HDAC inhibitor has a wide and remarkable proliferation inhibition effect.

The application finds that SDF4 in a body fluid sample can become a marker for detecting cancer patients with good sensitivity and specificity. By using a reagent for specifically detecting SDF4, gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected. The measurement of SDF4 in a body fluid sample is a detection method capable of detecting various cancers by a single test, and can be used for large-scale screening of cancers. In addition, early-stage cancers can be detected with good sensitivity and specificity, so that cancers can be found and treated in an early stage.

This disclosure particularly relates to combination therapy of oncolytic adenoviruses with topoisomerase I inhibitors or their prodrugs (such as topotecan or SN-38) or prodrugs of topoisomerase inhibitors (such as irinotecan) for the treatment or prevention of ovarian cancer, cervical cancer, lung cancer, colon or colorectal cancer and / or pancreatic cancer.

The invention belongs to the technical field of medicines, and relates to felodipine liposome as well as preparation and application thereof. The felodipine liposome disclosed by the invention comprises felodipine, phospholipid and cholesterol, wherein the mass ratio of the felodipine to the phospholipid is (1: 8)-(1: 20); the mass ratio of the phospholipid to the cholesterol is (5: 1)-(20: 1); furthermore, the felodipine liposome can also contain octadecylamine, and the mass ratio of the cholesterol to the octadecylamine is (1: 1)-(1: 3). The invention also provides an application of the felodipine or the felodipine liposome or the freeze-dried powder of the felodipine liposome in preparation of antitumor drugs. The tumors are colorectal cancer, liver cancer, ovarian cancer and breast cancer, and especially have the strongest inhibition effect on the colorectal cancer.

The invention discloses a traditional Chinese medicine composition for resisting ovarian cancer and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine is characterized by being prepared from the following raw materials in parts by weight: 30 parts of astragalus membranaceus, 9 parts of dandelion, 9 parts of cyrtomium fortunei, 9 parts of sanguisorba officinalis, 9 parts of pericarpium citri reticulatae, 9 parts of honeysuckle, 9 parts of ginseng, 9 parts of cirsium japonicum, 9 parts of herba cepbalanoplosis segeti, 15 parts of longan aril, 15 parts of radix rehmanniae, 15 parts of eucommia ulmoides and 6 parts of pseudo-ginseng. The invention not only proves the phenotypic effects of the tonifying and cancer eliminating decoction for inhibiting the proliferation and migration of ovarian cancer cells and inducing apoptosis, but also finds that the effect of the tonifying and cancer eliminating decoction is closely related to the activation of inhibiting a PI3K-AKT signal channel for the first time, the scientific connotation of the tonifying and cancer eliminating decoction is clarified from the molecular level, and an important preclinical research foundation is laid for developing the tonifying and cancer eliminating decoction into a modern new traditional Chinese medicine for resisting ovarian cancer.

The application provides a CA125 antigen binding protein and application thereof, the CA125 antigen binding protein comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising CDR3 with the sequence shown in SEQ ID NO.7 or SEQ ID NO.13; the light chain variable region comprising CDR3 with the sequence shown in SEQ ID NO.10 or SEQ ID NO.16. The CA125 antigen binding protein is a rabbit-derived monoclonal antibody, has high specificity and affinity to CA125, can specifically bind to CA125 protein, and has important application value in the diagnosis of ovarian cancer.

The invention belongs to the field of medicinal chemistry, and particularly relates to a targeted drug coordinated metal complex as well as a preparation method and application thereof. The metal complex prepared by the invention is a ruthenium (II), iridium (III) and rhodium (III) complex coordinated with a targeted drug, the original biological activity of the ligand is remarkably optimized and improved by virtue of the synergistic effect between central metal ions and the ligand, the specific binding capacity of the ligand with a tumor cell target spot is enhanced, and the tumor cell target spot is further enhanced. The metal complex has a broad-spectrum and efficient anti-tumor activity, the action range of the metal complex can cover multiple common tumor types including but not limited to liver cancer, kidney cancer, breast cancer, ovarian cancer or colorectal cancer and the like, and an important technical support is provided for developing novel anti-tumor drugs with multiple target points and low toxic and side effects. The complex provided by the invention is novel in structure and good in anti-tumor activity, and has a good application prospect in the field of anti-tumor drugs.

The invention relates to the technical field of biological medicines, and particularly discloses a high-grade serous ovarian cancer (HGSOC) treatment strategy based on ANXA6 protein detection and regulation. The invention provides a method for evaluating the sensitivity of a patient to cisplatin chemotherapy by detecting the expression level of ANXA6 protein or a specific modification site thereof, and a composition comprising inhibiting the function of ANXA6 or combining with cisplatin. In addition, the invention also relates to a medicine application for enhancing the chemotherapy effect by regulating the activity of ANXA6 related modifying enzyme.

A compound derivative is provided, where R in the compound of formula A is piperidine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

A novel 7-marker metabolite panel (7MetP) comprising or consisting of diacetylspermine, diacetylspermidine, N-(3-acetamidopropyl)pyrrolidin-2-one, Nacetylneuraminate, N-acetyl-mannosamine, N-acetyl-lactosamine, and hydroxyisobutyric acid is described.

The application discloses a series of derivatives based on natural product gelsemium methyl, pharmaceutically acceptable salts and preparation methods thereof. Bioactivity tests show that the compounds have the effect of inhibiting the proliferation of various tumor cells. The compounds can be used for the treatment of various cancers (including but not limited to gastric cancer, liver cancer, lung cancer, esophageal cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, nasopharyngeal cancer, ovarian cancer, kidney cancer, bladder cancer, thyroid cancer and skin cancer) as active pharmaceutical ingredients.

The invention relates to a detection device for early screening of ovarian cancer, comprising a box body which is provided with a test tube groove; the box body is provided with a plurality of elastic jacking structures for clamping test tubes, each elastic jacking structure comprises a guide gear rotationally connected to the box body, the guide gear is provided with at least three inclined grooves, and an acute included angle is formed between the groove direction of the inclined grooves and the radial direction of the guide gear; the at least three groups of clamping assemblies are connected to the box body and the chutes in a sliding manner, and the end parts of the clamping assemblies extend into the test tube grooves; the detection device further comprises a plurality of racks which are connected to the box body in a sliding mode, all the racks extend in the line or row direction of all the test tube grooves, and all the racks are meshed with all the guide gears located in the same line or row. The technical problems that an existing test tube is fixed by depending on friction force, so that the test tube is difficult to take out, a reagent easily shakes, and friction noise is generated can be solved.

The present invention relates to a tricyclic compound of formula (I) and its analogue useful for the treatment of breast and ovarian cancer. In particular, the present invention relates to novel tricyclic compound as PARP1 / 2 inhibitor, designed to block the activity of the enzyme Poly (ADP-ribose) polymerase (PARP1 / 2), which plays a crucial role in DNA damage repair, particularly in cancer cells. The synthesized inhibitor molecules having improved solubility, bioavailability and no haematological toxicity can be useful in potential cancer therapies, and defects in DNA repair pathways.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, gastrointestinal cancer, pancreatic cancer, prostate cancer, stromal cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The invention discloses a benzacridine-3, 4-dicarboximide derivative as well as a preparation method and application thereof, the structure of the benzacridine-3, 4-dicarboximide derivative is shown as I-A, and n is equal to 1, 2, 3 or 4; the invention also discloses hydrochloride of the benzacridine-3, 4-dicarboximide derivative and a preparation method, all the compounds are subjected to CCK-8 experiments to investigate the cytotoxicity to 14 tumor cells and human normal lung embryo fibroblasts, and the compound 4 with the best activity is used for evaluating the cytotoxicity to SK-OV-3 ovarian cancer cell proliferation and invasion, the cytotoxicity to SK-OV-3 ovarian cancer cells, the cytotoxicity to human normal lung embryo fibroblasts and the cytotoxicity to SK-OV-3 ovarian cancer cells and the cytotoxicity to human normal lung embryo fibroblasts. And influence of migration capability. Subsequently, in-vivo anti-tumor activity of the compound 4 is found in a nude mouse xenotransplantation tumor experiment, and whether the compound has toxicity to mice or not is observed through pathological tissue slices under the administration treatment concentration. The invention has great value in discovery of new anti-tumor small molecule drugs and research and development of clinical drugs thereof.

The invention discloses a PARP inhibitor sensitivity prediction method based on a specific cell cluster and application. The method comprises the following steps: acquiring an ovarian cancer tumor tissue sample of a subject; detecting whether a specific cell cluster exists in the sample or not, and determining the abundance of the specific cell cluster, wherein the specific cell cluster comprises an IFN epithelial cell cluster CN12 taking an IFN tumor cell as a center and / or a TAM enrichment cluster CN29 taking an M2 type tumor related macrophage as a center; according to the detection result, predicting according to at least one of the following rules: if the CN12 abundance before treatment is greater than 0.8%, the CN29 abundance before treatment is greater than 32.7%, the CN12 abundance after treatment is greater than 0.009%, the CN29 abundance after treatment is greater than 2.9%, or the SPP1 cell density before treatment is greater than 1.7%, predicting that the drug resistance is not sensitive or easily generated. The prediction model is established from a cell cluster space tissue level, and the method has the advantages of high prediction accuracy, flexible sample requirements, high operability and the like.